



Universiteit
Leiden
The Netherlands

Survival outcomes of patients with advanced mucosal melanoma diagnosed from 2013 to 2017 in the Netherlands: a nationwide population-based study

Zeijl, M.C.T. van; Boer, F.L.; Poelgeest, M.I.E. van; Eertwegh, A.J.M. van den; Wouters, M.W.J.M.; Wreede, L.C. de; ... ; Haanen, J.B.A.G.

Citation

Zeijl, M. C. T. van, Boer, F. L., Poelgeest, M. I. E. van, Eertwegh, A. J. M. van den, Wouters, M. W. J. M., Wreede, L. C. de, ... Haanen, J. B. A. G. (2020). Survival outcomes of patients with advanced mucosal melanoma diagnosed from 2013 to 2017 in the Netherlands: a nationwide population-based study. *European Journal Of Cancer*, 137, 127-135.
doi:10.1016/j.ejca.2020.05.021

Version: Publisher's Version

License: [Creative Commons CC BY 4.0 license](https://creativecommons.org/licenses/by/4.0/)

Downloaded from: <https://hdl.handle.net/1887/3182217>

Note: To cite this publication please use the final published version (if applicable).



Available online at www.sciencedirect.com

ScienceDirect

journal homepage: www.ejancer.com



Original Research

Survival outcomes of patients with advanced mucosal melanoma diagnosed from 2013 to 2017 in the Netherlands – A nationwide population-based study



Michiel C.T. van Zeijl^{a,b,1}, Florine L. Boer^{c,1},
 Mariëtte I.E. van Poelgeest^c, Alfons J.M. van den Eertwegh^d,
 Michel W.J.M. Wouters^{a,e}, Liesbeth C. de Wreede^f, Maureen J.B. Aarts^g,
 Franchette W.P.J. van den Berkmortel^h, Jan Willem B. de Grootⁱ,
 Geke A.P. Hospers^j, Djura Piersma^k, Rozemarijn S. van Rijn^l,
 Karijn P.M. Suijkerbuijk^m, Albert J. ten Tijeⁿ,
 Astrid A.M. van der Veldt^o, Gerard Vreugdenhil^p,
 Marye J. Boers-Sonderen^q, Ellen H.W. Kapiteijn^b,
 John B.A.G. Haanen^{r,*}

^a Scientific Department, Dutch Institute for Clinical Auditing, Rijsburgerweg 10, Leiden, 2333AA, the Netherlands

^b Department of Medical Oncology, Leiden University Medical Centre, Albinusdreef 2, Leiden, 2333ZA, the Netherlands

^c Department of Gynaecology, Leiden University Medical Centre, Albinusdreef 2, Leiden, 2333ZA, the Netherlands

^d Department of Medical Oncology, Amsterdam University Medical Centres (location VUmc), Cancer Centre Amsterdam, De Boelelaan 1117, 1081, HV Amsterdam, the Netherlands

^e Department of Surgical Oncology, Netherlands Cancer Institute, Plesmanlaan 121, Amsterdam, 1066CX, the Netherlands

^f Department of Biomedical Data Sciences, Leiden University Medical Centre, Albinusdreef 2, Leiden, 2333ZA, the Netherlands

^g Department of Medical Oncology, Maastricht University Medical Centre, P. Debyelaan 25, Maastricht, 6229 HX, the Netherlands

^h Department of Medical Oncology, Zuyderland Medical Centre Sittard, Dr. H. van der Hoffplein 1, Sittard-Geleen, 6162BG, the Netherlands

ⁱ Department of Medical Oncology, Isala Oncology Centre, Dokter van Heesweg 2, Zwolle, 8025AB, the Netherlands

^j Department of Medical Oncology, University Medical Centre Groningen, Hanzeplein 1, Groningen, 9713GZ, the Netherlands

^k Department of Internal Medicine, Medisch Spectrum Twente, Koningsplein 1, Enschede 7512KZ, the Netherlands

^l Department of Internal Medicine, Medical Centre Leeuwarden, Henri Dunantweg 2, Leeuwarden, 8934AD, the Netherlands

^m Department of Medical Oncology, University Medical Centre Utrecht, Heidelberglaan 100, Utrecht, 3584CX, the Netherlands

ⁿ Department of Internal Medicine, Amphia Hospital, Molengracht 21, Breda, 4818CK, the Netherlands

^o Departments of Medical Oncology and Radiology & Nuclear Medicine, Erasmus Medical Centre - Cancer Institute, 's-Gravendijkwal 230, Rotterdam, 3015CE, the Netherlands

^p Department of Internal Medicine, Maxima Medical Centre, De Run 4600, Eindhoven, 5504DB, the Netherlands

* Corresponding author: Fax: +31205122572.

E-mail address: j.haanen@nki.nl (J.B.A.G. Haanen).

¹ M.C.T. van Zeijl and F.L. Boer contributed equally to this article.

^a Department of Medical Oncology, Radboud University Medical Centre, Geert Grooteplein Zuid 10, Nijmegen, 6525GA, the Netherlands

^r Divisions of Medical Oncology and Molecular Oncology & Immunology, Netherlands Cancer Institute, Plesmanlaan 121, Amsterdam, 1066CX, the Netherlands

Received 11 March 2020; received in revised form 18 April 2020; accepted 20 May 2020

Available online 4 August 2020

KEYWORDS

Mucosal melanoma;
Advanced disease;
Prognostic factors;
Survival;
Immunotherapy

Abstract **Background:** Mucosal melanoma (MM) is rare and has a poor prognosis. Since 2011, new effective treatments are available for advanced melanoma. It is unclear whether patients with mucosal melanoma equally benefit from these new treatments compared with patients with cutaneous melanoma (CM).

Methods: Patients with advanced MM and CM diagnosed between 2013 and 2017 were included from a nationwide population-based registry – the Dutch Melanoma Treatment Registry. Overall survival (OS) was estimated with the Kaplan-Meier method (also for a propensity score-matched cohort). A Cox model was used to analyse the association of possible prognostic factors with OS.

Results: In total, 120 patients with MM and 2960 patients with CM were included. Median OS was 8.7 months and 14.5 months, respectively. Patients with MM were older (median age 70 versus 65 years) and more often female (60% versus 41%), compared with CM. In total, 77% and 2% of the MM patients were treated with first-line immunotherapy and targeted therapy, respectively, compared with 49% and 33% of the CM patients. In contrast to CM, OS for MM did not improve for patients diagnosed in 2015–2017, compared with 2013–2014. ECOG performance score ≥ 1 (HR = 1.99 [1.26–3.15; $p = 0.003$]) and elevated LDH level (HR = 1.63 [0.96–2.76]; $p = 0.069$) in MM were associated with worse survival.

Conclusions: Within the era of immune and targeted therapies, prognosis for patients with advanced MM has not improved as much as for CM. Collaboration is necessary to enlarge sample size for research to improve immunotherapeutic strategies and identify targetable mutations.

© 2020 Elsevier Ltd. All rights reserved.

1. Introduction

Primary mucosal melanoma (MM) is a rare type of cancer accounting for 1–2% of all melanomas [1,2]. In contrast to cutaneous melanoma (CM), the incidence of MM has not increased and lies between 0.2 and 0.4 cases per 100,000 people [3,4]. MM can originate from any mucosa-lined surface of the body, but the highest incidence is reported in the head and neck, vulvovaginal, anal and rectal region [5,6]. Because of the rareness of MM outcome data is scarce and mainly based on retrospective studies with the limited number of cases. MM is still a poorly understood disease.

In recent years, for advanced CM, effective immune and targeted therapies have improved overall survival (OS) [7]. However, it is unclear whether the prognosis of patients with advanced MM has changed in the new era of immune and targeted therapy. Melanomas arising from mucosal sites differ from CM

in clinical characteristics and prognosis. From primary diagnosis of any stage melanoma, the 5-year overall survival probability for MM and CM are 37% and 92%, respectively [3]. Advanced stage of disease at presentation and high recurrence rates of mucosal melanoma are responsible for the low survival probability. Other possible explanations for poor prognosis of MM are the low tumour mutational burden (leading to a low response to checkpoint inhibitors), the absence of targetable oncogenic drivers, the alleged biological aggressiveness and the rich lymphatic and vascular supply of the mucosa [6,8,9].

The aim of this study is to report real-world outcomes of patients with advanced MM and identify prognostic factors for OS. Furthermore, we aim to explore whether OS for patients with MM has improved after the introduction of immunotherapy. We used data from a nationwide population-based registry, in which all patients with unresectable stage

IIIC and stage IV melanoma in the Netherlands are registered.

2. Materials and methods

2.1. Study design

We performed a retrospective observational study analysing patients aged ≥ 18 years with unresectable stage IIIC or stage IV (advanced) mucosal or cutaneous melanoma diagnosed between 2013 and 2017 from the Dutch Melanoma Treatment Registry (DMTR). The DMTR prospectively collects data from all advanced melanoma patients in the Netherlands and has been described in detail in a previous publication [10]. Electronic patient records were checked again to determine if patients had an MM. Characteristics and survival outcomes of patients with advanced MM were compared with a control group of patients with advanced CM. The stage for CM and MM were determined as per the American Joint Committee on Cancer version [11]. Patients with MM were analysed by location of the primary tumour, categorised as head and neck region, upper gastrointestinal (oesophagus and stomach), lower gastrointestinal (anus and rectum) vulvovaginal, and other locations (location not further defined). Data-set cut-off date was 01-06-2019.

2.2. Statistical analysis

Baseline characteristics were analysed with descriptive statistics. Median follow-up was estimated with the reverse Kaplan-Meier method [12]. OS, estimated with the Kaplan-Meier method, was defined as time of diagnosis of advanced MM to death from any cause. OS of MM and CM was also compared by creating a propensity score-matched cohort. A matched CM cohort was created by using the propensity scores estimated based on the baseline variables age, gender, Eastern Cooperative Oncology Group Performance Score (ECOG PS), lactate dehydrogenase (LDH) level, distant metastases (<3 or ≥ 3 organ sites involved), brain and liver metastasis and BRAF mutational status. The algorithm of the nearest neighbour matching with 1:3 ratio was used. A Cox proportional hazards model was used to estimate the association of prognostic factors with OS; age, gender, ECOG PS, LDH level, brain and liver metastases and distant metastases (<3 or ≥ 3 organ sites involved) were included in the Cox models. We imputed missing covariates for the Cox model according to White and Royston (2009) using the multiple imputation by chained equation method and pooled coefficients as per Rubin's rules (100 imputations and 20 iterations) [13]. Statistical software used was R (version

Table 1

Patient characteristics of patients with mucosal and cutaneous melanoma at diagnosis of unresectable stage III or stage IV disease. Missing data $<2.5\%$ are not shown in this table.

Characteristics	Cutaneous (n = 2960)	Mucosal (n = 120)	P-value ^a
Median age, year (IQR)	65 [54, 73]	70 [62, 76]	
Months to advanced melanoma			
Median (IQR)	35 [14, 75]	9 [0, 21]	<0.001
Female	1212 (41.0)	72 (60.0)	<0.001
ECOG PS			
0	1448 (53.7)	57 (52.3)	0.647
1	866 (32.1)	39 (35.8)	
≥ 2	384 (14.2)	13 (11.9)	
Unknown	262	11	
LDH level			
Normal	1788 (63.5)	76 (69.7)	0.277
$1 \times$ ULN	3.5)	24 (22.0)	
$>2 \times$ ULN	366 (13.0)	9 (8.3)	
Unknown	146	11	
Stage			
III (unresectable)	230 (7.8)	15 (12.5)	<0.001
IV-M1a	222 (7.5)	7 (5.8)	
IV-M1b	318 (10.7)	17 (14.2)	
IV-M1c	1387 (46.9)	70 (58.3)	
IV-M1d	791 (26.7)	11 (9.2)	
Metastases in ≥ 3 organ sites	1330 (45.0)	36 (30.0)	0.002
Mutations			
BRAF	1649 (55.7)	7 (5.8)	<0.001
NRAS	625 (21.1)	17 (14.2)	0.042
KIT	39 (1.3)	14 (11.7)	<0.001
GNAQ	18 (0.6)	2 (1.7)	0.001
GNAI1	15 (0.5)	2 (1.7)	0.001

IQR - interquartile range, ECOG PS - Eastern Cooperative Oncology Group performance status, LDH - lactate dehydrogenase, ULN - upper limit of normal.

^a P-value of statistical tests comparing characteristics of patients with cutaneous and mucosal melanoma (excluding missing values). Values are n (%) unless otherwise indicated.

3.6.1: packages car, lubridate, tidyverse, survival, MatchIt and mice).

3. Results

3.1. Patient characteristics

From 2013 to 2017, 3974 patients were diagnosed with advanced melanoma. After exclusion of 894 patients with uveal, acral or melanoma of unknown origin, a total of 120 (3.0%) patients with MM and 2960 (96%) patients with CM were included in the study; supplement Fig. S1. Patients with MM were older, more often female, less often had stage IV-M1d disease and fewer distant metastases in ≥ 3 organ sites, but liver metastases were more frequent. The baseline characteristics of CM and MM are shown in Table 1.

MM was located in the head and neck region in 39 (33%) patients, in the vulvovaginal region in 29 (24%) patients and in the upper and lower gastrointestinal tract in 7 (5.8%) and 38 (32%) patients, respectively.

Seven patients (5.8%) had MM located at other primary location(s). The LDH level, ECOG score and stage of disease were similar between the different locations of MM. Median time from initial diagnosis until confirmed advanced stage disease was shorter for MM located in the upper and lower gastrointestinal tract than that in the vulvovaginal region and the head and neck region (0 and 6 months compared with 9 and 15 months, respectively). Baseline characteristics of MM by location are shown in the supplement (Table S1).

Oncogenic mutation(s) were less frequent for MM than for CM (Table 1). A BRAF mutation was found in 1649 (55.9%) patients with CM in seven of the 122 patients with MM (5.8%; five patients had V600E, one had V600R and one V600K, and one patient was classified as ‘other’ type BRAF mutation). NRAS and KIT mutations were found in 625 (21.1%) and 39 (1.3%) patients with CM and in 17 (14.2%) and 15 (11.7%) patients with MM, respectively (Table 1). Patients with MM originating in the head and neck region most often had NRAS mutations (eight [20.5%] patients). The KIT gene was most often mutated in MM located in the lower gastrointestinal tract and vulvovaginal region, in eight (21.1%) and four (13.8%) patients, respectively.

3.2. Treatment characteristics

Fifteen (12.5%) patients with advanced MM were treated with local therapy alone (surgery, radiotherapy, hyperthermia therapy, radiofrequency or microwave ablation), 89 (74.2%) patients with systemic (and local) therapy and 16 (13.3%) patients did not receive any treatment. First-line systemic therapy for patients with MM mostly consisted of immunotherapy; 43 (48.3%) patients received an anti-PD-1 antibody, 16 (18.0%) patients ipilimumab and nine (10.1%) patients ipilimumab plus nivolumab combination therapy. Best overall response (BOR) to immunotherapy was a complete response (CR) in four (5.9%) patients, partial response (PR) in 10 (14.7%) patients and stable disease (SD) in 16 (23.5%) patients. Of the patients with advanced CM, 271 (9.2%) patients received local therapy, 2440 (82.4%) patients were treated with systemic therapy and 249 (8.4%) patients received no treatment. First-line systemic therapy in CM consisted of anti-PD-1 antibodies in 709 (29.1%) patients, ipilimumab in 356 (14.6%) patients and ipilimumab plus nivolumab combination therapy in 133 (5.5%) patients. BOR to immunotherapy for CM was a CR in 154 (12.9%) patients, PR in 298 (24.9%) patients and SD in 335 (28.0%) patients. First-line BRAF inhibitors were used in 409 (16.8%) patients and combined BRAF plus MEK inhibitors in 401 (16.4%) patients. Distribution of all first-line systemic therapies used in CM and MM are shown in the supplement (Fig. S3).

3.3. Overall survival

Median follow-up was 38 months for MM and 34 months for CM. Median OS of all patients with advanced MM and CM was 8.9 months (95%CI: 7.3–12.7) and 14.5 months (95%CI: 13.7–15.4), respectively. The 1- and 3-year OS probabilities of patients with MM were 42% (95%CI: 34–52) and 15% (95%CI: 9.0–24; Fig. 1). For patients with CM, the 1- and 3-year OS probabilities were 55% (95%CI: 54–57) and 30% (95%CI: 29–32; Fig. 1). OS of CM in the propensity score-matched cohort (Table S2) was also associated with better OS in CM than MM (17.1 versus 10.8 months, $p = 0.003$; supplement Fig. S2).

Median OS of patients with MM diagnosed in 2013–2014 and in 2015–2017 was comparable (8.7 months [95%CI: 6.9–16.7] and 8.9 months [95%CI: 6.8–13.5], respectively), but median OS of patients with CM increased from 11.3 months (95%CI: 10.2–12.4) in 2013–2014 to 16.9 months (95%CI: 15.4–18.2) in 2015–2017 (Fig. 2a). Median OS of patients treated with systemic therapy was 11.8 months (95%CI: 8.8–16.1) for MM and 17.9 months (95%CI: 16.6–18.9) for CM (Fig. 2b). Median OS was 9.0 months (95%CI: 5.9–18.9) for lower gastrointestinal MM, 8.6 months (95%CI: 6.8–21) for vulvovaginal MM and 7.1 months (95%CI: 4.9–14) for head and neck MM (Fig. 3).

At the 3-year landmark 11 patients with MM were alive and in the follow-up. All of these ‘long-term’ survivors had a baseline ECOG PS of ≤ 1 ; seven patients had a normal LDH level, and three patients had a LDH level of $1 \times$ upper limit of normal. No patient had stage IV-M1d disease, and two (18.2%) patients had distant metastases in ≥ 3 organ sites (supplement




Fig. 1. Kaplan-Meier curves of overall survival of patients with unresectable stage III or stage IV mucosal versus cutaneous melanoma. OS = Overall survival, CI = confidence interval. (Log-rank test: $p < 0.001$).




Fig. 2. Kaplan-Meier curves of overall survival for unresectable stage III or stage IV mucosal and cutaneous melanoma of A) patients diagnosed in 2013 and 2014 versus 2015, 2016 and 2017 and B) stratified by treatment modality. OS = Overall survival, CI = confidence interval.

Table S3). Seven (63.6%) patients were treated with immunotherapy; three patients received an anti-PD-1 antibody, and of the four patients who received first-line ipilimumab, three patients received an anti-PD-1 antibody as second-line treatment. Of the remaining four patients, two patients were treated with local therapy and two patients with another systemic treatment.

3.4. Prognostic factors of survival

Distant metastases in ≥ 3 organ sites (hazard ratio [HR]: 1.56 [95%CI: 1.02–2.40; $p = 0.041$]), ECOG PS of ≥ 1 (HR 1.79 [95%CI: 1.17–2.75]; $p = 0.007$), elevated LDH level (HR 1.53 [95%CI: 0.96–2.43]; $p = 0.073$) and brain metastases (HR 1.84 [95%CI 0.94–3.59]; $p = 0.073$) (although the association of the latter two

was not statistically significant) were associated with death in the univariable Cox model for MM. ECOG PS of ≥ 1 (HR 1.99 [95%CI: 1.26–3.15]; $p = 0.003$) and elevated LDH level (HR 1.63 [95%CI: 0.96–2.76]; $p = 0.069$) were associated with death in the multivariable Cox model for MM. Age of 70 years and older was not significantly associated with death (HR 1.43 [95%CI: 0.93–2.21]; $p = 0.11$). The univariable and multivariable Cox models are shown in Table 2.

4. Discussion

To our knowledge, this is the first nationwide population-based cohort study of patients with advanced MM, reflecting the care and outcomes in the Netherlands of patients diagnosed from 2013 to 2017. Despite comparable baseline characteristics, the survival




Fig. 3. Kaplan-Meier curves of overall survival of patients with advanced mucosal melanoma stratified by location. Upper gastrointestinal ($n = 7$) and 'other' ($n = 7$) mucosal melanoma were excluded. mOS - median overall survival, CI - confidence interval.

of patients with MM was worse than that of patients with CM. This also holds for the subgroup of patients who were treated with systemic therapy. In contrast to patients with CM, OS of patients with MM did not

improve between 2013 and 2017, despite the introduction of novel therapies. Elevated LDH level and ECOG PS of ≥ 1 were independently associated with worse OS in MM. The prognosis of MM, originating from different types of primary locations appeared to be similar. NRAS (mainly in head and neck MM) and KIT mutations (mainly in gastrointestinal and vulvovaginal MM) were most common in MM.

Results of our cohort of advanced MM and CM confirm that patients with advanced MM have a worse prognosis than patients with CM [8,14]. Despite that patients with advanced MM had the favourable disease stage and similar ECOG PS and LDH levels compared with patients with advanced CM, outcomes for MM were worse. This suggests that MM has an inherent worse prognosis and it is hypothesised this may be due to a different, more aggressive, biological behaviour [8]. The clinical behaviour of MM and low tumour mutation burden with distinct driver mutations advocate that MM has a different pathogenesis than CM and should be seen as a unique entity of melanomas [2,6,15,16]. More studies found that MM less often metastasise to the brain and that lungs, liver and/or non-regional lymph nodes are involved most frequently [17–21]. Similar to CM and consistent with the literature for advanced MM, we found that the ECOG score of ≥ 1 and the elevated LDH level were independent prognostic factors for OS [15,17,22].

Table 2

Univariable and multivariable Cox regression model for the association of prognostic factors with overall survival for mucosal melanoma. There was a total of 100 events.

Variable	Univariable				Multivariable ^a		
	<i>n</i>	HR	95% CI	<i>P</i> -value	HR	95% CI	<i>P</i> -value
Age							
≤69 years	59	1.08	(0.73–1.61)	0.692	1.43	(0.93–2.21)	0.107
≥70 years	61	1			1		
Gender							
Male	48	1			1		
Female	72	0.80	(0.53–1.19)	0.267	0.88	(0.58–1.34)	0.548
ECOG PS							
0	57	1			1		
≥1	52	1.79	(1.17–2.75)	0.007	1.99	(1.26–3.15)	0.003
LDH level							
Normal	76	1			1		
>ULN	33	1.53	(0.96–2.43)	0.073	1.63	(0.96–2.76)	0.069
Distant metastases							
<3 organ sites	84	1			1		
≥3 organ sites	36	1.56	(1.02–2.4)	0.041	1.16	(0.68–1.99)	0.577
Liver metastasis							
No	58	1			1		
Yes	44	1.41	(0.91–2.19)	0.123	1.03	(0.63–1.7)	0.895
Brain metastasis							
Absent	91	1			1		
Present	11	1.84	(0.94–3.59)	0.073	1.43	(0.68–3)	0.346

HR = hazard ratio, CI = confidence interval, ECOG PS = ECOG performance score, LDH = lactate dehydrogenase, ULN = upper limit of normal.

^a Multivariable model are pooled results after multiple imputation.

From 2011 to 2016, immune and targeted therapies gradually became available for patients with advanced melanoma in the Netherlands [23]. Unlike for CM, we did not observe an increase in OS for MM when comparing the cohorts of 2013–2015 to 2016–2017. However, the median OS of patients with MM who received systemic therapy in our cohort is comparable with the median OS of post-hoc analysis of patients with MM in the pembrolizumab trials (respectively 11.8 months and 11.3 months), and it is higher than the historical median OS of 6–8 months for advanced melanoma in general [11,24,25]. It also resembles the median OS of 11.5 months in patients with MM treated with nivolumab after progression on or after ipilimumab, although OS was defined from start of nivolumab treatment [26].

From currently available treatment options for advanced MM, immunotherapy has the potential to induce durable remissions, although much less frequently compared with advanced CM. Ipilimumab monotherapy has shown to have some antitumour activity in advanced MM, but overall response rates (ORRs) were lower than those in CM (<10%) [14,27,28]. The post-hoc analysis of the KEYNOTE 001, 002, –006 trials showed an ORR of 19% and a median OS of 11.3 months for MM patients treated with pembrolizumab [24]. A median OS of 11.5 months was found in the CHECKMATE-172 study, in which OS was defined from start of nivolumab on or after progression of ipilimumab [26]. Pooled analysis of the CheckMate studies compared effectiveness of ipilimumab, nivolumab and ipilimumab plus nivolumab in MM and observed the highest potential for the ipilimumab plus nivolumab, but no information on long-term outcomes is available (ORR of 8.3%, 23.3% and 37.1%, respectively) [29]. An immunotherapeutic strategy that has shown the promising ORR in advanced cutaneous and uveal melanoma is adoptive cell therapy with tumour-infiltrating lymphocytes [30], but effectiveness data specifically for MM are lacking. MM-specific vaccine development will remain challenging given the low tumour neo-antigen burden [31].

Patients with a BRAF-mutated MM can benefit from BRAF plus MEK inhibitors, but BRAF mutations are rare in MM [32–35]. KIT and NRAS mutations are more common, and additionally, we observed KIT mutation was more frequent in lower gastrointestinal and vulvovaginal MM [34,35]. KIT is a targetable driver mutation, and KIT inhibitors have demonstrated clinical activity in advanced melanoma, but ORR and survival benefit varied by the type of KIT alteration [9]. Within the DMTR, no data are captured on the use of imatinib or another c-KIT inhibitor for KIT mutated MM. It is clear that systemic treatment for MM is lagging behind its cutaneous counterpart. Research should be focused on identifying vulnerabilities specific for MM

and attempt to target these with either immunotherapies or targeted therapies.

Some small studies on MM, in which all stages of MM were analysed, have found that localisation of MM was predictive of survival. Head, neck and gastrointestinal MM of any stage appeared to have inferior survival compared with other MM [15,36]. However, three large studies on prognostic factors for survival in MM found that location was not a prognostic factor for the early or advanced stage [8,37,38]. Cui *et al.* [37] even conclude that MM can be staged as a single group irrespective of location of MM. Our results endorse that survival between the subtypes of advanced MM is comparable, but imbalances in baseline characteristics of patients between the subtypes of advanced melanoma and low number of patients do not allow a fair comparison of OS.

A major limitation is the small sample size hampering analysis and adequate correction for confounding factors when comparing outcomes. Still, this is one of the largest real-world cohorts of MM that gives insight in the outcomes in recent years.

5. Conclusion

Survival of patients with advanced MM is worse than that in advanced CM. In the era of immune and targeted therapies, prognosis for patients with advanced MM has not improved as much as the prognosis of CM. The aim of future research should be to gain further knowledge on the vulnerabilities of MM to target these with novel strategies. We emphasise the need for international collaboration allowing data exchange to increase sample size and research on this rare disease.

Funding

The Dutch Institute for Clinical Auditing foundation received a start-up grant for the Dutch Melanoma Treatment Registry (DMTR) from governmental organisation The Netherlands Organization for Health Research and Development (ZonMW, project number 836002002). The DMTR is structurally funded by Bristol Myers Squibb, Merck Sharpe & Dohme, Novartis and Roche Pharma. Roche Pharma stopped funding in 2019 and Pierre Fabre started funding of the DMTR in 2019. For this work no funding was granted.

Conflict of interest statement

M.C.T.v.Z., F.L.B., M.I.E.v.P., L.C.d.W., M.W.J.M.W., M.J.B.S., M.J.B.A., F.W.P.J.v.d.B., D.P., R.S.v.R., A.J.t.T., G.V., J.v.d.H. have no conflicts of interest to disclose. A.J.M.v.d.E. reports having advisory relationships with Amgen, Bristol-Myers

Squibb, Roche, Novartis, MSD, and Pierre Fabre. J.W.B.d.G. reports receiving personal fees outside the submitted work from Bristol-Myers Squibb, Roche, Pierre Fabre, Servier, MSD, Novartis. G.A.P.H. reports having consultancy/advisory relationships with Amgen, Bristol-Myers Squibb, Roche, MSD, Pfizer, Novartis and receiving research grants not related to this paper from Bristol-Myers Squibb, and Seerave. E.H.W.K. reports having consultancy/advisory relationships with Amgen, Bristol-Myers Squibb, Novartis, Roche, Merck, Pierre Fabre, Eisai, Bayer, Genzyme-Sanofi and receiving research grants not related to this paper from Novartis and Bristol-Myers Squibb. K.P.M.S. reports having advisory relationships with Bristol-Myers Squibb, Roche, Novartis, MSD, and Pierre Fabre. A.A.M.v.d.V. reports having consultancy relationships with Bristol-Myers Squibb, MSD, Roche, Novartis, Pierre Fabre, Pfizer, Sanofi, Ipsen, and Eisai. J.B.A.G.H. reports having advisory relationships with Amgen, AstraZeneca, Bayer, Bristol-Myers Squibb, Celsius Therapeutics, GSK, Immunocore, Ipsen, MSD, Merck Serono, Novartis, Neon Therapeutics, Pfizer, Roche/Genentech, Sanofi, Seattle Genetics and receiving research grants not related to this paper from Novartis, Bristol-Myers Squibb, MSD, Neon Therapeutics. All grants were paid to the institutions. The funders had no role in the writing of this article or decision to submit it for publication.

Authors have full control of all primary data. They agree to allow the journal to review the data if requested.

Appendix A. Supplementary data

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.ejca.2020.05.021>.

References

- [1] Bishop KD, Olszewski AJ. Epidemiology and survival outcomes of ocular and mucosal melanomas: a population-based analysis. *Int J Canc* 2014;134:2961–71. <https://doi.org/10.1002/ijc.28625>.
- [2] Lerner BA, Stewart LA, Horowitz DP, Carvajal RD. Mucosal melanoma: new insights and therapeutic options for a unique and aggressive disease. *Oncology (Williston Park)* 2017;31:e23–32.
- [3] Che G, Huang B, Xie Z, Zhao J, Yan Y, Wu J, et al. Trends in incidence and survival in patients with melanoma, 1974–2013. *Am J Canc Res* 2019;9:1396–414.
- [4] Mikkelsen LH, Larsen A-C, von Buchwald C, Drzewiecki KT, Prause JU, Heegaard S. Mucosal malignant melanoma - a clinical, oncological, pathological and genetic survey. *APMIS* 2016;124:475–86. <https://doi.org/10.1111/apm.12529>.
- [5] Altieri L, Wong MK, Peng DH, Cockburn M. Mucosal melanomas in the racially diverse population of California. *J Am Acad Dermatol* 2017;76:250–7. <https://doi.org/10.1016/j.jaad.2016.08.007>.
- [6] Yde SS, Sjoegren P, Heje M, Stolle LB. Mucosal melanoma: a literature review. *Curr Oncol Rep* 2018;20. <https://doi.org/10.1007/s11912-018-0675-0>.
- [7] Schadendorf D, van Akkooi ACJ, Berking C, Griewank KG, Gutzmer R, Hauschild A, et al. Melanoma. *Lancet* 2018;392:971–84. [https://doi.org/10.1016/S0140-6736\(18\)31559-9](https://doi.org/10.1016/S0140-6736(18)31559-9).
- [8] Kuk D, Shoushtari AN, Barker CA, Panageas KS, Munhoz RR, Momtaz P, et al. Prognosis of mucosal, uveal, acral, nonacral cutaneous, and unknown primary melanoma from the time of first metastasis. *Oncol* 2016;21:848–54. <https://doi.org/10.1634/theconcologist.2015-0522>.
- [9] Meng D, Carvajal RD. KIT as an oncogenic driver in melanoma: an update on clinical development. *Am J Clin Dermatol* 2019;20:315–23. <https://doi.org/10.1007/s40257-018-0414-1>.
- [10] Jochems A, Schouwenburg MG, Leeneman B, Franken MG, van den Eertwegh AJM, Haanen JBAG, et al. Dutch Melanoma Treatment Registry: quality assurance in the care of patients with metastatic melanoma in The Netherlands. *Eur J Canc* 2017;72:156–65. <https://doi.org/10.1016/j.ejca.2016.11.021>.
- [11] Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, et al. Final version of 2009 AJCC melanoma staging and classification. *J Clin Oncol* 2009;27:6199–206. <https://doi.org/10.1200/JCO.2009.23.4799>.
- [12] Schemper M, Smith TL. A note on quantifying follow-up in studies of failure time. *Contr Clin Trials* 1996;17:343–6.
- [13] White IR, Royston P. Imputing missing covariate values for the Cox model. *Stat Med* 2009;28:1982–98. <https://doi.org/10.1002/sim.3618>.
- [14] Postow MA, Kuk D, Bogatch K, Carvajal RD. Assessment of overall survival from time of metastasis in mucosal, uveal, and cutaneous melanoma. *J Clin Oncol* 2014;32. https://doi.org/10.1200/jco.2014.32.15_suppl.9074. 9074–9074.
- [15] Minhahn H, Geunlee K, Choi W, Cheong SH, Myung KB, Hahn HJ. An updated review of mucosal melanoma: survival meta-analysis. *Mol Clin Oncol* 2019;11:116–26. <https://doi.org/10.3892/mco.2019.1870>.
- [16] Newell F, Kong Y, Wilmott JS, Johansson PA, Ferguson PM, Cui C, et al. Whole-genome landscape of mucosal melanoma reveals diverse drivers and therapeutic targets. *Nat Commun* 2019;10:3163. <https://doi.org/10.1038/s41467-019-11107-x>.
- [17] Shoushtari AN, Bluth MJ, Goldman DA, Bitas C, Lefkowitz RA, Postow MA, et al. Clinical features and response to systemic therapy in a historical cohort of advanced or unresectable mucosal melanoma. *Melanoma Res* 2017;27:57–64. <https://doi.org/10.1097/CMR.0000000000000306>. Lippincott Williams and Wilkins.
- [18] Zhou R, Shi C, Tao W, Li J, Wu J, Han Y, et al. Analysis of mucosal melanoma whole-genome landscapes reveals clinically relevant genomic aberrations. *Clin Canc Res* 2019;25:3548–60. <https://doi.org/10.1158/1078-0432.CCR-18-3442>.
- [19] Grözinger G, Mann S, Mehra T, Klumpp B, Grosse U, Nikolaou K, et al. Metastatic patterns and metastatic sites in mucosal melanoma: a retrospective study. *Eur Radiol* 2016;26:1826–34. <https://doi.org/10.1007/s00330-015-3992-9>.
- [20] O'Regan K, Breen M, Ramaiya N, Jagannathan J, DiPiro PJ, Hodi FS, et al. Metastatic mucosal melanoma: imaging patterns of metastasis and recurrence. *Canc Imag* 2013;13:626–32. <https://doi.org/10.1102/1470-7330.2013.0055>.
- [21] Lian B, Cui CL, Zhou L, Song X, Zhang XS, Wu D, et al. The natural history and patterns of metastases from mucosal melanoma: an analysis of 706 prospectively-followed patients. *Ann Oncol Off J Eur Soc Med Oncol* 2017;28:868–73. <https://doi.org/10.1093/annonc/mdw694>.
- [22] Manola J, Atkins M, Ibrahim J, Kirkwood J. Prognostic factors in metastatic melanoma: a pooled analysis of Eastern Cooperative Oncology Group trials. *J Clin Oncol* 2000;18:3782–93. <https://doi.org/10.1200/JCO.2000.18.22.3782>.
- [23] Van Zeijl MCT, Van Den Eertwegh AJM, Wouters MWJM, Jochems A, Schouwenburg MG, Haanen JBAG, et al. Recent treatment results for metastatic melanoma: data from the Dutch melanoma treatment registry. *Ned Tijdschr Geneesk* 2018;162.

- [24] Hamid O, Robert C, Ribas A, Hodi FS, Walpole E, Daud A, et al. Antitumour activity of pembrolizumab in advanced mucosal melanoma: a post-hoc analysis of KEYNOTE-001, 002, 006. *Br J Canc* 2018;119:670–4. <https://doi.org/10.1038/s41416-018-0207-6>.
- [25] Korn EL, Liu PY, Lee SJ, Chapman JAW, Niedzwiecki D, Suman VJ, et al. Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. *J Clin Oncol* 2008;26:527–34. <https://doi.org/10.1200/JCO.2007.12.7837>.
- [26] Nathan P, Ascierto PA, Haanen J, Espinosa E, Demidov L, Garbe C, et al. Safety and efficacy of nivolumab in patients with rare melanoma subtypes who progressed on or after ipilimumab treatment: a single-arm, open-label, phase II study (CheckMate 172). *Eur J Canc* 2019;119:168–78. <https://doi.org/10.1016/j.ejca.2019.07.010>.
- [27] Schadendorf D, Hodi FS, Robert C, Weber JS, Margolin K, Hamid O, et al. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. *J Clin Oncol* 2015;33:1889–94. <https://doi.org/10.1200/JCO.2014.56.2736>.
- [28] Del Vecchio M, Di Guardo L, Ascierto PA, Grimaldi AM, Sileni VC, Pigozzo J, et al. Efficacy and safety of ipilimumab 3 mg/kg in patients with pretreated, metastatic, mucosal melanoma. *Eur J Canc* 2014;50:121–7. <https://doi.org/10.1016/j.ejca.2013.09.007>.
- [29] D'Angelo SP, Larkin J, Sosman JA, Lebbé C, Brady B, Neyns B, et al. Efficacy and safety of nivolumab alone or in combination with ipilimumab in patients with mucosal melanoma: a pooled analysis. *J Clin Oncol* 2017;35:226–35. <https://doi.org/10.1200/JCO.2016.67.9258>.
- [30] Rohaan MW, Van Den Berg JH, Kvistborg P, Haanen JBAG. Adoptive transfer of tumor-infiltrating lymphocytes in melanoma: a viable treatment option 11 medical and Health sciences 1107 immunology 11 medical and Health sciences 1112 Oncology and carcinogenesis. *J Immunother Canc* 2018;6:102. <https://doi.org/10.1186/s40425-018-0391-1>.
- [31] Guo X, Gao S, Yang L, Fang J, Wei G, Ma X, et al. Analysis of Chinese acral and mucosal melanoma patient genomic and neo-antigen profiles in cancer vaccine development: a pilot study. *J Clin Oncol* 2019;37. <https://doi.org/10.1200/jco.2019.37.15-suppl.e14300>. e14300–e14300.
- [32] Long GV, Stroyakovskiy D, Gogas H, Levchenko E, De Braud F, Larkin J, et al. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. *Lancet* 2015;386:444–51. [https://doi.org/10.1016/S0140-6736\(15\)60898-4](https://doi.org/10.1016/S0140-6736(15)60898-4).
- [33] Ascierto PA, McArthur GA, Dréno B, Atkinson V, Liskay G, Di Giacomo AM, et al. Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. *Lancet Oncol* 2016;17:1248–60. [https://doi.org/10.1016/S1470-2045\(16\)30122-X](https://doi.org/10.1016/S1470-2045(16)30122-X).
- [34] Nassar KW, Tan AC. The mutational landscape of mucosal melanoma. *Semin Canc Biol* 2019. <https://doi.org/10.1016/j.semcancer.2019.09.013>.
- [35] Hintzsche JD, Gorden NT, Amato CM, Kim J, Wuensch KE, Robinson SE, et al. Whole-exome sequencing identifies recurrent SF3B1 R625 mutation and comutation of NF1 and KIT in mucosal melanoma. *Melanoma Res* 2017. <https://doi.org/10.1097/CMR.0000000000000345>.
- [36] Al-Hasani A, Vrabie A, Qureshi MM, Mathews S, Pollock S, Truong M-T, et al. Survival outcomes of mucosal melanoma in the USA. *Future Oncol* 2019;15:3977–86. <https://doi.org/10.2217/fon-2019-0465>.
- [37] Cui CL, Lian B, Zhou L, Song X, Zhang XS, Wu D, et al. Multifactorial analysis of prognostic factors and survival rates among 706 mucosal melanoma patients. *Ann Surg Oncol* 2018;25:2184–92. <https://doi.org/10.1245/s10434-018-6503-9>.
- [38] Heppt MV, Roesch A, Weide B, Gutzmer R, Meier F, Loquai C, et al. Prognostic factors and treatment outcomes in 444 patients with mucosal melanoma. *Eur J Canc* 2017;81:36–44. <https://doi.org/10.1016/j.ejca.2017.05.014>.